ArticleFrontiers in oncology2025
The expression of mercaptopyruvate sulfurtransferase serves as a potential biomarker for prognostic stratification and immunotherapy in certain cancers.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: 3 - Mercaptopyruvate Sulfurtransferase (3 - MST) is an enzyme encoded by the Mercaptopyruvate Sulfurtransferase (MPST) gene. The enzyme is associated with a variety of cancers such as lung adenocarcinoma. However, there is a lack of comprehensive pan-cancer analysis on the potential impact of MPST on cancer diagnosis, prognosis, and immune response. Methods: Based on data from The Cancer Genome Atlas and the Human Protein Atlas, we conducted a comprehensive bioinformatic analysis to investigate the oncogenic role of MPST. Immune-related characteristics and tumor microenvironment infiltration were assessed using TIMER2.0. Protein-protein interaction networks were constructed via STRING, while DNA methylation differences across cancers were analyzed with UALCAN. Further insights into genetic alterations and functional states at the single-cell level were obtained from cBioPortal and CancerSEA. Finally, clinical samples were collected and subjected to immunohistochemical staining to preliminarily validate the bioinformatic findings. Result: The research assessed the links between MPST levels and various cancer outcomes, genetic alterations, immune cell presence, and DNA methylation patterns. Single-cell sequencing was utilized to deepen our comprehension of its functional importance. Furthermore, the unique immunohistochemical profiling of MPST in patient tissue was confirmed. Significant expression differences between tumors and normal tissues in certain cancer types suggest a correlation between MPST expression and clinical outcomes. Furthermore, correlations exist between MPST expression levels in different immune cells and the tumor immune microenvironment. Our observations also indicate a role for MPST methylation, along with the advantageous effects of highly amplified mutations and deletions of the MPST gene. Discussion: Significantly, MPST shows potential for early cancer identification and as a predictive factor for various tumor forms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.